Antisense strategies targeting protein kinase C: preclinical and clinical development
Seminars in Oncology, ISSN: 0093-7754, Vol: 30, Issue: 4 SUPPL. 10, Page: 26-31
2003
- 44Citations
- 8Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations44
- Citation Indexes44
- 44
- CrossRef23
- Captures8
- Readers8
Article Description
Altered protein kinase C-α (PKC-α) expression has been implicated in tumor promotion and carcinogenesis. One potentially attractive therapeutic intervention may be the use of selective antisense oligonucleotides to inhibit production of PKC-α. In preclinical studies, the antisense oligonucleotide LY900003 (ISIS 3521;Affinitak; Isis Pharmaceuticals, Carlsbad, CA) has shown selective inhibition of PKC-α mRNA and protein expression and has shown antitumor activity. In clinical studies, LY900003 has shown activity as a single agent, but the most promising data have been obtained in combination with chemotherapy, particularly in patients with non-small cell lung cancer. Data from phase I and II studies have led to ongoing randomized phase III trials in combination with either cisplatin and gemcitabine or carboplatin and paclitaxel. Studies in other tumor types will also investigate the benefit of combining LY900003 with conventional chemotherapy.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0093775403002823; http://dx.doi.org/10.1016/s0093-7754(03)00282-3; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0042466484&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/12917818; http://linkinghub.elsevier.com/retrieve/pii/S0093775403002823; http://api.elsevier.com/content/article/PII:S0093775403002823?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0093775403002823?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S0093775403002823; http://dx.doi.org/10.1016/s0093-7754%2803%2900282-3; https://dx.doi.org/10.1016/s0093-7754%2803%2900282-3
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know